You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

HALOPERIDOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Haloperidol, and what generic alternatives are available?

Haloperidol is a drug marketed by Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Rubicon, SCS, Teva, Teva Pharms, Abraxis Pharm, Baxter Hlthcare Corp, Epic Pharma Llc, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, Actavis Group, Aiping Pharm Inc, Chartwell Rx, Duramed Pharms Barr, Innogenix, Lederle, MSN, Mylan, Par Pharm, Purepac Pharm, Quantum Pharmics, Royce Labs, Sciegen Pharms Inc, Strides Pharma, Upsher Smith Labs, Zydus Pharms Usa, Hospira, Mankind Pharma, Meitheal, Sandoz, Somerset Theraps Llc, Zydus Pharms, and Actavis Mid Atlantic. and is included in one hundred and seven NDAs.

The generic ingredient in HALOPERIDOL is haloperidol decanoate. There are twenty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Haloperidol

A generic version of HALOPERIDOL was approved as haloperidol decanoate by FRESENIUS KABI USA on December 19th, 1997.

  Try a Trial

Drug patent expirations by year for HALOPERIDOL
Drug Prices for HALOPERIDOL

See drug prices for HALOPERIDOL

Drug Sales Revenue Trends for HALOPERIDOL

See drug sales revenues for HALOPERIDOL

Recent Clinical Trials for HALOPERIDOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Christian HassagerPhase 3
Qilu Pharmaceutical Co., Ltd.Phase 3
Cancer Prevention Research Institute of TexasPhase 2/Phase 3

See all HALOPERIDOL clinical trials

Pharmacology for HALOPERIDOL
Medical Subject Heading (MeSH) Categories for HALOPERIDOL
Anatomical Therapeutic Chemical (ATC) Classes for HALOPERIDOL

US Patents and Regulatory Information for HALOPERIDOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan HALOPERIDOL haloperidol TABLET;ORAL 070278-001 Jun 10, 1986 AB RX No Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scs HALOPERIDOL haloperidol TABLET;ORAL 070725-001 Sep 24, 1986 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx HALOPERIDOL haloperidol TABLET;ORAL 071209-003 Nov 17, 1986 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.